Foghorn Therapeutics Stock Alpha and Beta Analysis
| FHTX Stock | USD 5.19 0.21 3.89% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Foghorn Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Foghorn Therapeutics over a specified time horizon. Remember, high Foghorn Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Foghorn Therapeutics' market risk premium analysis include:
Beta 2.3 | Alpha 0.074 | Risk 4.8 | Sharpe Ratio 0.0567 | Expected Return 0.27 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Foghorn Therapeutics Backtesting, Foghorn Therapeutics Valuation, Foghorn Therapeutics Correlation, Foghorn Therapeutics Hype Analysis, Foghorn Therapeutics Volatility, Foghorn Therapeutics History and analyze Foghorn Therapeutics Performance. Foghorn Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Foghorn Therapeutics market risk premium is the additional return an investor will receive from holding Foghorn Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Foghorn Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Foghorn Therapeutics' performance over market.| α | 0.07 | β | 2.30 |
Foghorn Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Foghorn Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Foghorn Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Foghorn Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Foghorn Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Foghorn Therapeutics shares will generate the highest return on investment. By understating and applying Foghorn Therapeutics stock market price indicators, traders can identify Foghorn Therapeutics position entry and exit signals to maximize returns.
Foghorn Therapeutics Return and Market Media
The median price of Foghorn Therapeutics for the period between Tue, Sep 30, 2025 and Mon, Dec 29, 2025 is 4.45 with a coefficient of variation of 8.91. The daily time series for the period is distributed with a sample standard deviation of 0.4, arithmetic mean of 4.53, and mean deviation of 0.3. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Volatility clustering patterns for Foghorn Therapeutics Inc. - Market Risk Analysis Smart Allocation Stock Reports - newser.com | 10/24/2025 |
2 | Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update | 11/05/2025 |
3 | This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note Here Are Top 3 Initiations For Friday - Benzinga | 11/07/2025 |
4 | Wedbush Predicts Stronger Earnings for Foghorn Therapeutics | 11/11/2025 |
5 | Insider Trading | 11/14/2025 |
6 | Can Foghorn Therapeutics Inc. stock maintain growth trajectory - Market Volume Summary Safe Capital Growth Tips - newser.com | 11/18/2025 |
7 | Foghorn Therapeutics Upgraded at Wall Street Zen - MarketBeat | 11/28/2025 |
8 | Stifel initiates Foghorn Therapeutics stock with Buy rating, 12 target By Investing.com - Investing.com India | 12/03/2025 |
9 | BTIG Research Upgrades Foghorn Therapeutics to Strong-Buy | 12/19/2025 |
10 | Foghorn Therapeutics Inc. Receives Consensus Recommendation of Buy from Analysts - MarketBeat | 12/26/2025 |
About Foghorn Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Foghorn or other stocks. Alpha measures the amount that position in Foghorn Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 1.24 | 1.07 | 0.68 | 0.88 | Revenue Per Share | 0.46 | 0.81 | 0.41 | 0.28 |
Foghorn Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Foghorn Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Foghorn Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Foghorn Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Foghorn Therapeutics. Please utilize our Beneish M Score to check the likelihood of Foghorn Therapeutics' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Foghorn Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.